How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.